Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency

American Journal of Veterinary Research

Volumn 64, Issue 3, 2003, Pages 321-327

  Brown, Scott A ^a   Finco, Delmar R ^a   Brown, Cathy A ^a   Crowell, Wayne A ^a   Alva, Roberto ^b   Ericsson, Glenn F ^b   Cooper, Tanya ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CAPILLARY PRESSURE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DOG; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION RATE; HYPERTENSION; HYPERTROPHY; INTERSTITIUM; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY TUBULE; KIDNEY TUMOR; MALE; MEASUREMENT; NONHUMAN; PARTIAL NEPHRECTOMY; PROTEIN URINE LEVEL; PROTEINURIA; RENOVASCULAR HYPERTENSION; TIME; ANIMAL; ANIMAL DISEASE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GLOMERULUS; METABOLISM; PATHOPHYSIOLOGY; VASCULARIZATION;

ANIMALIA; CANIS FAMILIARIS; GLOMERULUS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; DOGS; ENALAPRIL; FEMALE; HYPERTROPHY; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; MALE; PEPTIDYL-DIPEPTIDASE A; TIME FACTORS;

EID: 0037945525     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2003.64.321     Document Type: Article

References (41)

1. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983; 23:647-655.
2. Brown SA, Crowell WA, Brown CA, et al. Pathophysiology and management of progressive renal disease. Br Vet J 1997; 154:93-109.
3. Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F92.
4. Bidani AK, Schwartz MM, Lewis EJ. Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol 1987;252:F1003-F1010.
5. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 1989;35:654-660.
6. Finco DR, Brown SA, Brown CA, et al. Progression of chronic renal disease in the dog. J Vet Intern Med 1999;13:516-528.
7. Brown SA, Finco DR, Crowell WA, et al. Single-nephron adaptations to partial renal ablation in the dog. Am J Physiol 1990; 258:F495-F503.
8. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
9. Bidani AK, Mitchell KD, Schwartz MM, et al. Absence of glomerular injury or nephron loss in a normotensive rat remnant kidney model. Kidney Int 1990;38:28-38.
10. Brown SA, Walton CA, Crawford P, et al. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993;43:1210-1218.
11. Brown SA, Brown CA, Crowell WA, et al. Beneficial effects of chronic administration of dietary omega-3 polyunsaturated fatty acids in dogs with renal insufficiency. J Lab Clin Med 1998;131:447-455.
12. Grauer G, Greco D, Gretzy D, et al. Effects of enalapril treatment versus placebo as a treatment for canine idiopathic glomerulonephritis. J Vet Intern Med 2000;14:526-533.
13. Grodecki K, Gains M, Jacobs R, et al. ACE inhibitor treatment of chronic renal failure in a canine model of hereditary nephritis. Vet Pathol 1995;32:555.
14. Brown SA, Crowell WA, Barsanti JA, et al. Beneficial effects of dietary mineral restriction in dogs with marked reduction of functional renal mass. J Am Soc Nephrol 1991;1:1169-1179.
15. Brown SA, Brown CA, Jacobs G, et al. Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency. Am J Vet Res 2001;62:375-383.
16. Brown SA, Finco DR, Crowell WA, et al. Dietary protein intake and the glomerular adaptations to partial nephrectomy in dogs. J Nutr 1991;121:S125-S127.
17. Navar LG, Rosivall L. Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics. Kidney Int 1984;25:857-868.
18. Hall JE, Guyton AC, Jackson TE, et al. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 1977;233:F366-F372.
19. Rosivall L, Narkates AJ, Oparil S, et al. De novo intrarenal formation of angiotensin II during control and enhanced renin secretion. Am J Physiol 1987;252:F1118-F1123.
20. Navar L, Harrison-Bernard L, Wang C, et al. Concentrations and actions of intraluminal angiotensin II. J Am Soc Nephrol 1999; 10:S189-S195.
21. Navar LG. Renal autoregulation: perspectives from whole kidney and single nephron studies. Am J Physiol 1978;234:F357-F370.
22. Brown S, Finco D, Navar L. Impaired renal autoregulatory ability in dogs with reduced renal mass. J Am Soc Nephrol 1995; 5:1168-1174.
23. Garcia T, Cardeal da Costa J, Costa R, et al. Acute tubular necrosis in kidney transplant patients treated with enalapril. Ren Fail 1994;16:419-423.
24. VanDe Ven P, Beutler J, Kaatee R, et al. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 1998;53:986-993.
25. Barnett R, Singhal PC, Scharschmidt LA, et al. Dopamine attenuates the contractile response to angiotensin II in isolated rat glomeruli and cultured rat mesangial cells. Circ Res 1986;59:529-533.
26. Ennulat D, Brown S. Canine and equine mesangial cell culture. In Vitro 1995;31:574-578.
27. Cartwright M, Jaenke RS. Effects of dietary protein and captopril on glomerular permselectivity in rats with unilateral nephrectomy. Lab Invest 1988;59:492-499.
28. Gruden G, Thomas S, Burt D, et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999;10:730-737.
29. Levey A, Greene T, Beck G, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? J Am Soc Nephrol 1999;10:2426-2439.
30. Brenner BM, Meyer TW, Hostetter TH. The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652-659.
31. Taylor X, Sunthornyothin S. The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers. Curr Hypertens Rep 1999;1:446-453.
32. Textor S, Canzanello V. Importance of blood pressure reduction for prevention of progression of renal disease. Curr Hypertens Rep 1999;1:423-430.
33. Ruggenenti P, Remuzzi G. The role of protein traffic in the progression of renal diseases. Annu Rev Med 2000;51:315-327.
34. Rossert J, Terraz-Durasnel C, Brideau G. Growth factors, cytokines, and renal fibrosis during the course of diabetic nephropathy Diabete Metab 2000;26:S16-S24.
35. Wolf G, Ziyadeh F. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997;29:153-163.
36. Yoshida Y, Kawamura M, Ikoma M, et al. Effects of antihypertensive drugs on glomerular morphology. Kidney Int 1989; 36:626-635.
37. Singh R, Alavi N, Singh A, et al. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabete Metab 1999;48:2066-2073.
38. Wolf G. Angiotensin as a renal growth promoting factor. Adv Exp Med Biol 1995;377:225-236.
39. Orth S, Weinreich T, Bonisch S, et al. Angiotensin II induces hypertrophy and hyperplasia in adult human mesangial cells. Exp Nephrol 1995;3:23-33.
40. Klahr S, Ishidoya S, Morrissey J. Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Am J Kidney Dis 1995;26:141-146.
41. Lefebvre H, Laroute V, Concordet D, et al. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. J Vet Intern Med 1999;13:21-27.